News from and about New Century Pharmaceuticals News and Events
  About NCP Technologies Products Opportunities News Home  
 

News

October 2011, New Century licenses magnetic properties of its Ferrigen platform to Integrated Magnetic Systems in Dundee, Scotland. Read More »

2010 New Century published overview of its CADEX albumin structural survey as an invited chapter in Burger’s Drug Design and Development: D.C. Carter, “Crystallographic Survey of Albumin Drug Interaction and Applications in Cancer Chemotherapy,” Burger’s Drug Design and Development, 7th Edition, John Wiley & Sons; 437-468 (2010).


December 2010, F-star licenses therapeutic applications with Boehringer Ingelheim. Read More »


May 2009, New Century licenses its recombinant product portfolio to Albumin Therapeutics. Read More »


New Investment Opportunity: New Century Pharmaceuticals announces its pending August 2008 stock offering to fund the Company's first Phase I clinical trial. Read More »


June 2008, New Century Pharmaceuticals, Inc., one of the Hudson Alpha Associate Companies, establishes initial office presence at the Hudson Alpha Institutes new state-of-the-art facilities. Read More »


Bob Crutchfield, CEO of Third Trimester and former VP of US Oncology, is engaged by the Company as a senior advisor in support of business operations and development. Read More »


May 23, 2008 NCP successfully retires bridge financing through sale of its royalty interest in modular antibody platform licensed to f-star, an Austrian based biopharmaceutical company. Read More »


In the first quarter of 2006, New Century Pharmaceuticals, Inc. jointly engaged Harpeth Capital, LLC and BioPharm Development Group, LLC. Harpeth Capital is a middle-market investment banking firm based in Nashville, Tennessee focusing primarily in healthcare. BioPharm is a biotech and pharmaceutical consulting firm also based in Nashville, Tennessee.


NCP's ferritin technology platform featured on the cover of the summer issue of the journal Industrial Biotechnology. The work provided a dramatic demonstration of the platform on an HIV vaccine application.
See more »


The Company's first Ferrigen patent entitled, "Ferritin Fusion Proteins for use in Vaccines and other Applications," issues on August 29th, 2006, U.S. Patent No. 7,097,841.

  Site Map Contact Directions